At the time of writing, Denali Therapeutics Inc [DNLI] stock is trading at $14.78, up 4.08%. An important factor to consider is whether the stock is rising or falling in short-term value. The DNLI shares have gain 2.43% over the last week, with a monthly amount drifted -20.54%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Deutsche Bank started tracking the stock with Buy rating on February 11, 2025, and set its price target to $31. On January 07, 2025, Robert W. Baird initiated with a Outperform rating and assigned a price target of $31 on the stock. William Blair started tracking the stock assigning a Outperform rating. Stifel upgraded its rating to a Buy but $37 remained the price target by the analyst firm on December 16, 2024. In a note dated October 07, 2024, Cantor Fitzgerald downgraded an Neutral rating on this stock.
For the past year, the stock price of Denali Therapeutics Inc fluctuated between $13.67 and $33.33. Currently, Wall Street analysts expect the stock to reach $38.5 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $14.78 at the most recent close of the market. An investor can expect a potential return of 160.49% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.31 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.25 points at the first support level, and at 13.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.07, and for the 2nd resistance point, it is at 15.37.
Ratios To Look Out For
It is important to note that Denali Therapeutics Inc [NASDAQ:DNLI] has a current ratio of 8.46. On the other hand, the Quick Ratio is 8.46, and the Cash Ratio is 1.71.
Transactions by insiders
Recent insider trading involved Ho Carole, Chief Medical Officer, that happened on Jan 06 ’25 when 12255.0 shares were sold. Chief Medical Officer, Ho Carole completed a deal on Jan 07 ’25 to sell 2907.0 shares. Meanwhile, COFO and Secretary Schuth Alexander O. sold 12255.0 shares on Jan 06 ’25.
